Adverse effects of GLP – 1 Receptor Agonists by Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska

Get full text

GLP-1 Receptor Agonists’ Impact on Fertility - A Review by Joanna Wojda, Katarzyna Lesiczka-Fedoryj, Anna Walczak, Zuzanna Kościuszko, Adam Sobiński, Matylda Czerwonka, Katarzyna Kurza, Julianna Podolec, Silvia Ciraolo, Agnieszka Kulczycka-Rowicka

Get full text

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes by María Isabel del Olmo-Garcia, Juan Francisco Merino-Torres

Get full text

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective by Dominique Xavier Brown, Marc Evans

“…This results in increased glucose dependent insulin synthesis and release. GLP-1 receptor agonists such as liraglutide and exenatide exert an intrinsic biological effect on GLP-1 receptors directly stimulating the release of insulin from pancreatic beta cells. …”
Get full text

GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy by Jena Velji-Ibrahim, Piyush Nathani, Harsh K Patel, Prateek Sharma

Get full text

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks by Ioannis Ilias, Lina Zabuliene, Manfredi Rizzo

Get full text

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties by Chenqi Lu, Cong Xu, Jun Yang

Subjects: Get full text

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition by Shasha Tian, Saijun Zhou, Weixi Wu, Yao lin, Tongdan Wang, Haizhen Sun, A‐Shan‐Jiang A‐Ni‐Wan, Yaru Li, Chongyang Wang, Xiaogang Li, Pei Yu, Yanjun Zhao

Subjects: Get full text

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence by Srikanth Krishnan, Pratyaksh K. Srivastava, Jayram Attaluri, Rebecca Nayeri, Dhananjay Chatterjee, Jay Patel, Ali Nsair, Matthew Budoff, Arash Nayeri

Subjects: “…GIP GLP-1 receptor agonist…”
Get full text

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes by Bethany Murphy, Simran Chahal, Elleigh Shepherd, Nicole Taylor, Austin Camp

Subjects: Get full text

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials by Haoyang Guo, Juan Yang, Jihan Huang, Ling Xu, Yinghua Lv, Yexuan Wang, Jiyuan Ren, Yulin Feng, Qingshan Zheng, Lujin Li

“…The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. …”
Get full text

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? by Chloé Amouyal, Fabrizio Andreelli

“…In 2005, the commercialization of GLP-1 receptor agonists gave the possibility to test this hypothesis. …”
Get full text

The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis by Xiaorui Lyu, Taibiao Lyu, Xue Wang, Huijuan Zhu, Hui Pan, Linjie Wang, Hongbo Yang, Fengying Gong

Get full text

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review by Sanbao Chai, Yapin Niu, Fengqi Liu, Shanshan Wu, Zhirong Yang, Feng Sun

Get full text

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice by Marwa Al‐Badri, Shilton Dhaver, Osama Hamdy

Subjects: “…GLP‐1 receptor agonists…”
Get full text

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review by Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek

Subjects: Get full text

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study by Hiroya Kitsunai, Yuka Shinozaki, Sho Furusawa, Naoyuki Kitao, Miki Ito, Hiroyoshi Kurihara, Chiho Oba-Yamamoto, Jun Takeuchi, Akinobu Nakamura, Yumi Takiyama, Hiroshi Nomoto

Subjects: “…GLP-1 receptor agonist…”
Get full text

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review by Andrijana Koceva, Andrijana Koceva, Katarina Mlekuš Kozamernik, Katarina Mlekuš Kozamernik, Andrej Janež, Andrej Janež, Rok Herman, Rok Herman, Simona Ferjan, Simona Ferjan, Mojca Jensterle, Mojca Jensterle

Subjects: Get full text

Appendicitis After Initiation of Tirzepatide by Chan G, Ansar M, Klein M

Subjects: “…glp1 receptor agonists…”
Get full text

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic revi... by Song Liu, Jiaqiang Hu, Chen Zhao, Hang Liu, Chunyang He

Subjects: “…GLP-1 receptor agonists…”
Get full text